Treatment of Patients With Anxiety Disorder (0777-022)

A Double-Blind, Mulitcenter, Placebo-Controlled, Flexible-Dose Replicate Study of MK0777 Gel Extrusion Module (GEM) 3 mg B.I.D. to 8 mg B.I.D. in the Treatment of Outpatients With Generalized Anxiety Disorder

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00539578

Enrollment

270

Registered

2007-10-04

Start date

2002-09-30

Completion date

2003-02-28

Last updated

2015-11-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Generalized Anxiety Disorder

Brief summary

The purpose of the study is to examine the safety and efficacy of MK0777 during treatment for Generalized Anxiety Disorder.

Interventions

DRUGMK0777

Duration of Treatment: 4 weeks

DRUGComparator: placebo (unspecified)

Duration of Treatment: 4 weeks

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

* Male and Female patients ages 18 to 70

Exclusion criteria

* Women who are breastfeeding or pregnant * Positive result at prestudy on urine drug screen for illicit drugs * History of alcohol or drug abuse

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026